Role of Fluorodeoxyglucose PET in Inflammatory Bowel Disease: A Review

PET Clinics

Volumn 1, Issue 2, 2006, Pages 153-162

  Kresnik, Ewald ^a   Mikosch, Peter ^a   Gallowitsch, Hans Juergen ^a   Kohlfürst, Susanne ^a   Igerc, Isabell ^a   Lind, Peter ^a  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37349060361     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2006.02.002     Document Type: Review

References (91)

1. Woods G., Gutierrez Y., Walker D., et al. Diagnostic pathology of infectious disease (1993), Lea & Febiger, Philadelphia
2. Goldenberg D.M., Sharkey R.M., Udem S., et al. Immunoscintigraphy of Pneumocystis carinii pneumonia in AIDS patients. J Nucl Med 35 (1994) 1028-1034
3. Locher J.T., Seybold K., Andres R.Y., et al. Imaging of inflammatory and infectious lesions after injection of radioiodinated monoclonal antigranulocyte antibodies. Nucl Med Commun 7 (1986) 659-670
4. Becker W., Bair J., Behr T., et al. Detection of soft tissue infections and osteomyelitis using a technetium-99m-labeled antigranulocyte monoclonal antibody fragment. J Nucl Med 35 (1994) 1436-1443
5. Kresnik E., Gallowitsch H.J., Mikosch P., et al. Immunoscintigraphy of an inflammatory bowel process in Crohn's disease with a technetium-99m-labelled fragment (MN3 Fab′) and with an intact monoclonal anti-granulocyte antibody (Mab BW 250/183). Clin Nucl Med 24 (1999) 64-65
6. Kapsoritakis A.N. 99m-Tc-leukoscan in the evaluation of inflammatory bowel disease. Eur J Nucl Med 29 (2002) 1098
7. Stokkel M.P.M., Reigman H.I.E., and Pauwels E.K.J. Scintigraphic head-to-head comparison between 99mTc-WBCs and 99mTc-leukoscan in the evaluation of inflammatory bowel disease: a pilot study. Eur J Nucl Med 29 (2002) 251-254
8. Kolkman J.J., Falke T.H., Roos J.C., et al. Computed tomography and granulocyte scintigraphy in active inflammatory bowel disease. Comparison with endoscopy operative findings. Dig Dis Sci 41 (1996) 641-650
9. Gallowitsch H.J., Heinisch M., Mikosch P., et al. Tc-99m ciprofloxacin in clinically selected patients suspected for peripheral osteomyelitis, spondylodiscitis and fever of unknown origin: preliminary results. Nuklearmedizin 41 (2002) 30-36
10. Bomanji J., Solanki K.K., Britton K.E., et al. Imaging infection with Tc-99m-radiolabelled "infecton". Eur J Nucl Med 20 (1993) 834
11. Becker W., Fleig W., Marienhagen J., et al. Diagnostische Bedeutung der intestinalen Aktivität bei der Immunszintigraphie mit Tc-99m-NCA-95-Antikörpern. Nuklearmedizin 229 (1990) 47-48
12. Seggara I., Roca M., Ballielas C., et al. Granulocyte-specific monoclonal antibody technetium-99m BW 250/183 and In-111-oxine labelled leukocyte scintigraphy in inflammatory bowel disease. Eur J Nucl Med 18 (1991) 715-719
13. Becker W., Goldenberg D.M., Wolf F., et al. The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. Semin Nucl Med 24 (1994) 1-13
14. Mahida Y.R., Perkins A.C., Frier M., et al. Monoclonal granulocyte antibody in inflammatory bowel disease: a preliminary report. Nucl Med Commun 13 (1992) 330-335
15. Fischbach W., Mössner J., Seyschab H., et al. Tissue carcinoembryonic antigen and DNA aneuploidy in precancerous and cancerous colorectal lesions. Cancer 65 (1990) 1820-1824
16. Serafini A.N., Garty I., Vargas-Cuba R., et al. Clinical evaluation of a scintigraphic method for diagnosing inflammations/infections using indium-111-labeled nonspecific human IgG. J Nucl Med 32 (1991) 2227-2232
17. Becker W., Fischbach W., Reiners C., et al. Three phase blood cell scan: diagnostic validity in abdominal inflammatory diseases. J Nucl Med 27 (1986) 1109-1115
18. Weldon M.J., Joseph E.A., Frech A., et al. Comparison of 99m Tc hexamethylpropylene-amine oxime labelled leukocyte with 111-indium tropolonate labelled granulocyte scanning and ultrasound in the diagnosis of intraabdominal abscess. Gut 37 (1995) 557-564
19. Wheeler J.G., Slack N.F., Duncan A., et al. The diagnosis of intra-abdominal abscesses in patients with severe Chiron's disease. Q J Med 82 (1992) 159-167
20. Saverymuttu S.H., Maltby P., Batman P., et al. False positive localisation of indium-111 granulocytes in colonic carcinoma. Br J Radiol 59 (1986) 373-377
21. Spinellei F., Milella M., Sara R., et al. The 99mTc-HMPAO leukocyte scan: an alternative to radiology and endoscopy in evaluating the extent and the activity of inflammatory bowel disease. J Nucl Biol Med 35 (1991) 82-87
22. Even-Sapir E., Barnes D.C., Martin R.H., et al. Indium-111-white blood cell scintigraphy in Crohn's patients with fistulae and sinus tracts. J Nucl Med 35 (1994) 245-250
23. Gibson P., Lichtenstein M., Salehi N., et al. Value of positive technetium-99m leukocyte scans in predicting intestinal inflammations. Gut 32 (1991) 1502-1507
24. Ivancevic V., and Munz D.L. Nonspecific bowel activity in 99mTc-labelled monoclonal anti-granulocyte antibody imaging. Nucl Med Commun 13 (1992) 899-900
25. Lantto E., Jarvi K., Krekela I., et al. Technetium-99m hexamethyl propylene amine oxine leukocytes in the assessment of disease activity in inflammatory bowel disease. Eur J Nucl Med 19 (1992) 14-18
26. Weldon M.J., Masoomi A.M., Britten A.J., et al. Quantification of inflammatory bowel disease activity using technetium-99m HMPAO labelled leukocyte single photon emission computerized tomography (SPECT). Gut 36 (1995) 243-250
27. Allan R.A., Sladen G.E., Bassingham S., et al. Comparison of simultaneous 99mTc-HMPAO and 111In oxine labelled white cell scans in the assessment of inflammatory bowel disease. Eur J Nucl Med 20 (1993) 195-200
28. Arndt J.W., Van der Sluys Veer A., Block D., et al. Prospective comparative study of Tc-99m-WBCs and indium-111 granulocytes for the examination of inflammatory bowel disease. J Nucl Med 34 (1993) 1052-1057
29. Allan R.A., Sladen G.E., Bassingham S., et al. Comparison of simultaneous Tc-99m-HMPAO and indium-111-oxine labelled white blood cell scans in the assessment of inflammatory bowel disease. Eur J Nucl Med 20 (1993) 195-200
30. Saverymuttu S.H., Peters A.M., Crofton M.E., et al. 111-Indium autologous granulocytes in the detection of inflammatory bowel disease. Gut 26 (1985) 955-960
31. Charron M., Del Rosario F., and Kocoshis S. Assessment of terminal ileal and colonic inflammation in Crohn's disease with 99m-Tc-WBC. Acta Pediatr 88 (1999) 193-198
32. Kerry J.E., Marshall C., Griffiths P.A., et al. Comparison between Tc-HMPAO labelled white cells and Tc leukoscan in the investigation of inflammatory bowel disease. Nucl Med Commun 26 (2005) 245-251
33. Peters A.M., Danpure H.J., Osman S., et al. Clinical experience with 99m-Tc-hexamethylpropylene-amineoxime for labeling leukocytes and imaging inflammation. Lancet 2 (1986) 946-949
34. Scholmerich J., Schmidt E., Shumichen C., et al. Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using Tc-99m hexamethylpropyleneamine oxime as a leukocyte label. Gastroenterology 95 (1998) 1287-1293
35. Lachter J., Isserof H.N., Yasin K., et al. Radiolabeled leukocyte imaging in inflammatory bowel disease: a prospective blinded evaluation. Hepatogastroenterology 53 (2003) 1439-1441
36. Saverymuttu S.H., Peters A.M., Hodgson H.J., et al. Indium-111 leukocyte scanning: comparison with radiology for imaging of colon in inflammatory bowel disease. BMJ 285 (1982) 255-257
37. Lind P., Langsteger W., Költringer P., et al. Immunoscintigraphy of inflammatory processes with a technetium-99m labelled monoclonal antibody (Mab BW 250/183). J Nucl Med 31 (1990) 417-423
38. Paecock K., Porn U., Howman-Giles R., et al. 99m Tc-stannous colloid white cell scintigraphy in childhood inflammatory bowel disease. J Nucl Med 45 (2004) 261-265
39. Hughes D.K. Nuclear medicine and infection detection: the relative effectiveness of imaging with 111In-oxine-, 99mTc-HMPAO-, and 99mTc-stannous fluoride colloid-labeled leukocytes and with 67Ga-citrate. J Nucl Med Technol 31 (2003) 196-201
40. Del Rosario M.A., Fitzgerald J.F., Siddiqui A.R., et al. Clinical applications of Tc-99m hexamethyl propylene amine oxime leukocyte scan in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 28 (1999) 63-70
41. Guimbaud R., Beades E., Chauvelot-Moachon L., et al. Technetium 99m hexamethyl propylene amine oxime leukocyte scintigraphy in patients with ulcerative colitis : correlation with clinical, biologic, endoscopic, and pathologic intensity, and local release of interleukin 8. Gastrointest Endosoc 48 (1998) 491-496
42. Barabino A., Gattorno M., Cabria M., et al. 99mTc-white cell scanning to detect gut inflammation in children with inflammatory bowel disease or spondyloarthropathies. Clin Exp Rheumatol 16 (1998) 327-334
43. Sciarretta G., Furno A., Mazzoni M., et al. Technetium-99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: diagnostic and clinical relevance. Gut 34 (1993) 1364-1369
44. Wheeler J.G., Baker A.J., and Slack N.F. Case report: extensive uptake of 99mTc-HMPAO labelled leukocytes in the small bowel of patient with mesenteric ischemia. Clin Radiol 53 (1998) 227-228
45. Fisher M.F., and Rudd T.G. In-111-labeled leukocyte imaging: false positive study due to acute gastrointestinal bleeding. J Nucl Med 24 (1983) 803-804
46. Saverymuttu S.H., Crofton M.E., Peters A.M., et al. Indium-111 tropolonate leukocyte scanning in the detection of intra-abdominal abscesses. Clin Radiol 34 (1983) 593-596
47. Reske S., Bares R., Büll U., et al. Klinische Wertigkeit der Positronenemissionstomographie (PET) bei onkologischen Fragestellungen: Ergebnisse einer interdisziplinären Konsensuskonferenz. Nuklearmedizin 35 (1996) 42-52
48. Mac Keehan W.L. Glycolysis, glutaminolysis and cell proliferation. Cell Biol Int 6 (1982) 635-650
49. Weber G. Enzymology of cancer cells. N Engl J Med 296 (1977) 541-551
50. Zhuang H., and Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 32 (2002) 47-59
51. Alavi A., and Zhuang H. Finding infection-help from PET. Lancet 38 (2001) 1386
52. Paik J.Y., Lee C.H., Choe Y.S., et al. Augmented 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase. J Nucl Med 45 (2004) 124-128
53. Sasaki M., Ichiya Y., Kuwabara Y., et al. Ringlike uptake of F-18- FDG in brain abscess: a PET study. J Comput Assist Tomogr 14 (1990) 486-487
54. Osman S., and Danpure H.J. The use of 2-(18) fluoro-2-deoxy-d-glucose as a potential in vitro agent for labeling human granulocytes for clinical studies by positron emission tomography. J Radiat Appl Instrum 19 (1992) 183-190
55. Forstrom L.A., Mullan B.P., Hung J.C., et al. 18F-FDG labelling of human leukocytes. Nucl Med Commun 21 (2000) 691-694
56. Becker W., and Meller J. The role of nuclear medicine in infection and inflammation. Lancet Infect Dis 1 (2001) 326-333
57. Guhlmann A., Brech-Krauss D., Suger G., et al. Chronic osteomyelitis: detection with FDG PET and correlative histopathologic findings. Radiology 206 (1998) 749-754
58. Brudin L.H., Valind S.O., Rhodes C.G., et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 21 (1994) 297-305
59. Love C., Tomas M.B., Tronco G.G., et al. FDG PET of infection and inflammation. Radiographics 25 (2005) 1357-1368
60. Meyer M.A. Diffusely increased colonic F-18 FDG uptake in acute enterocolitis. Clin Nucl Med 20 (1995) 434-435
61. Hannah A., Scott A.M., Akhurst T., et al. Abnormal colonic accumulation of fluorine-18-FDG in pseudomembranous colitis. J Nucl Med 37 (1996) 1683-1685
62. Kresnik E., Mikosch P., Gallowitsch H.J., et al. F-18 fluorodeoxyglucose positron emission tomography in the diagnosis of inflammatory bowel disease. Clin Nucl Med 26 (2001) 867
63. Larson S.M. Cancer or inflammation? A holy grail for nuclear medicine [editorial]. J Nucl Med 35 (1994) 1653-1655
64. Bischof Delaloye A., and Wahl R.L. How high level of FDG abdominal activity is considered normal? [abstract]. J Nucl Med 36 Suppl (1995) 106P
65. Yasuda S., Takahashi W., Takagi S., et al. Factors influencing physiological FDG uptake in the intestine. Tokaj J Exp Clin Med 23 (1998) 241-244
66. Kostakoglu L., Wong J.C.H., Barrington S.F., et al. Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med 37 (1996) 1771-1773
67. Stahl A., Weber W.A., Avril N., et al. Effect of N-butyl-scopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin 39 (2000) 214-245
68. Kim S., Chung J.K., Kim B.T., et al. Relationship between gastrointestinal F-18-fluorodeoxyglucose accumulation and gastrointestinal symptoms in whole-body PET. Clin Positron Imaging 2 (1999) 273-280
69. Jadvar H., Schambye R.B., and Segall G.M. Effect of atropine and sincalide on the intestinal uptake of F-18 fluorodeoxyglucose. Clin Nucl Med 24 (1999) 965-967
70. Cook G.J.R., Fogelman I., and Maisey M.N. Normal physiological and benign pathological variants of 18-fluoro-deoxyglucose positron emission tomography scanning: potential for error in interpretation. Semin Nucl Med 26 (1996) 308-314
71. Tadlidil R., Jadvar H., Badin J.R., et al. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 224 (2002) 783-787
72. Meyer M.A. Diffusely increased colonic F-18 FDG uptake in acute enterocolitis. Clin Nucl Med 20 (1995) 434-435
73. Ruf J., Griebenow B., Stiller B., et al. Detection of infectious colitis by 18F-fluorodeoxyglucose-positron emission tomography in a child receiving intensive care after surgery. Pediatr Radiol 35 (2005) 702-705
74. Lorenzen J., Buchert R., and Bohuslavizki K.H. Value of FGDG PET in patients with fever of unknown origin. Nucl Med Commun 22 (2001) 779-783
75. Bleecker-Rovers C.P., Kleijn E., Corstens F.H.M., et al. Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging 31 (2004) 29-37
76. Miraldi F., Vesselle H., Faulhaber P.F., et al. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 23 (1998) 3-7
77. Neurath M.F., Schunk V., Holtmann M., et al. Noninvasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 97 (2002) 1978-1985
78. Bicik I., Bauerfeind P., Breitenbach T., et al. Inflammatory bowel disease activity measured by positron-emission tomography. Lancet 350 (1997) 262
79. Kresnik E., Gallowitsch H.J., Mikosch P., et al. 18F-FDG positron emission tomography in the early diagnosis of enterocolitis: preliminary results. Eur J Nucl Med 29 (2002) 1389-1392
80. De Winter F., van de Wiele C., Vogelaers D., et al. Fluorine-18 fluorodeoxyglucose-positron emission tomography: a highly accurate imaging modality for the diagnosis of chronic musculoskeletal infections. J Bone Joint Surg Am 83 (2001) 651-660
81. Sugawara Y., Braun D.K., Kison P.V., et al. Rapid detection of human infections with fluorine 18 fluorodeoxyglucose and positron emission tomography: preliminary results. Eur J Nucl Med 25 (1998) 1238-1243
82. Sugawara Y., Gutowsky T.D., Fisher S.J., et al. Uptake of positron emission tomography tracers in experimental bacterial infections: a comparative biodistribution study of radiolabeled FDG, thymidine, L-methionine, 67Ga-citrate, and 125I-HSA. Eur J Nucl Med 26 (1996) 333-341
83. Pio B.S., Byrne F.R., Aranda R., et al. Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-(18F)fluoro-D-glucose-labeled white blood cells. Mol Imaging Biol 5 (2003) 271-277
84. Zhuang H., Pourdehnad M., Lambright E.S., et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory process. J Nucl Med 42 (2001) 1412-1417
85. Ichiya Y., Kuwabaka Y., Sasaki M., et al. FDG-PET in infectious lesions: The detection and assessment of lesion activity. Ann Nucl Med 10 (1996) 185-191
86. Daley J.M., Shearer J.D., Mastrofrancesco B., et al. Glucose metabolism in injured tissue. A longitudinal study. Surgery 107 (1990) 187-192
87. West J., Morton D.J., Esmann V., et al. Carbohydrate metabolism in leukocytes. Metabolic activities of the macrophage. Arch Biochem Biophys 124 (1968) 85-90
88. Anderson R.L., and Wood W.A. Carbohydrate metabolism in microorganisms. Annu Rev Microbiol 23 (1969) 539-578
89. Igerc I., Gallowitsch H.J., Kohlfürst S., et al. The incremental value of combined 18F-fluorodeoxyglucose (FDG)-PET/contrast enhanced computed tomography (ceCT) in oncology patients in reducing false positive results [abstract]. Eur J Nucl Med 32 Suppl (2005) S154
90. Sun X.G., Xiu L.R., Wan L.R., et al. Oral contrast agent during PET/CT scan could increase FDG uptake in colon and rectum [abstract]. Eur J Nucl Med 32 Suppl (2005) S80
91. Hausegger K., Reinprecht P., Kau T., et al. Clinical experience with a commercially available negative oral contrast medium in PET/CT. Fortschr Rontgenstr 177 (2005) 796-799